Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T12:45:25.347Z.
Calculation as of: 2026-10-06T12:45:25.347Z.
Quote observation: 2026-10-05T19:59:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a6fb48ec682e3cf9a2a3de0b7f1962f0667ac92b413acd908fc1cfb112ec24a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apollomics, Inc. (APLM) | $50.51M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $49.96M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $49.50M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $49.40M | 11.31x | 6.17x | 6.96x | 6.04x |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $46.79M | N/A | 7.97x | 11.01x | 11.01x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
